CN103463314A - 一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法 - Google Patents
一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法 Download PDFInfo
- Publication number
- CN103463314A CN103463314A CN2013104588501A CN201310458850A CN103463314A CN 103463314 A CN103463314 A CN 103463314A CN 2013104588501 A CN2013104588501 A CN 2013104588501A CN 201310458850 A CN201310458850 A CN 201310458850A CN 103463314 A CN103463314 A CN 103463314A
- Authority
- CN
- China
- Prior art keywords
- grams
- herba
- stagnation
- blood stasis
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 55
- 210000004369 blood Anatomy 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010004142 Bartholinitis Diseases 0.000 title claims abstract description 23
- 239000006210 lotion Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 6
- 239000009806 pulsatillae Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 229940126678 chinese medicines Drugs 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 229940126673 western medicines Drugs 0.000 abstract 2
- 241000722824 Ardisia crenata Species 0.000 abstract 1
- 241001407382 Berberis julianae Species 0.000 abstract 1
- 241001195282 Bidens biternata Species 0.000 abstract 1
- 244000104272 Bidens pilosa Species 0.000 abstract 1
- 235000010662 Bidens pilosa Nutrition 0.000 abstract 1
- 241000405421 Breynia Species 0.000 abstract 1
- 240000005250 Chrysanthemum indicum Species 0.000 abstract 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 abstract 1
- 241000332747 Dysosma versipellis Species 0.000 abstract 1
- 240000005702 Galium aparine Species 0.000 abstract 1
- 235000014820 Galium aparine Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000003365 Ilex pubescens Nutrition 0.000 abstract 1
- 241001100932 Ilex pubescens Species 0.000 abstract 1
- 241000522169 Lespedeza Species 0.000 abstract 1
- 241001571764 Lysimachia christinae Species 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 240000000275 Persicaria hydropiper Species 0.000 abstract 1
- 235000017337 Persicaria hydropiper Nutrition 0.000 abstract 1
- 241000206469 Pulsatilla Species 0.000 abstract 1
- 240000005746 Ruta graveolens Species 0.000 abstract 1
- 235000001347 Ruta graveolens Nutrition 0.000 abstract 1
- 240000001519 Verbena officinalis Species 0.000 abstract 1
- 235000018718 Verbena officinalis Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 description 24
- 230000001737 promoting effect Effects 0.000 description 23
- 239000003440 toxic substance Substances 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 14
- 208000004880 Polyuria Diseases 0.000 description 14
- 230000035619 diuresis Effects 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 206010020751 Hypersensitivity Diseases 0.000 description 12
- 230000007815 allergy Effects 0.000 description 12
- 208000026935 allergic disease Diseases 0.000 description 10
- 210000002429 large intestine Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 241000594558 Labium Species 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000003905 vulva Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241001313288 Labia Species 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003119 painkilling effect Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000860 cochlear nerve Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000001720 vestibular Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010049244 Ankyloglossia congenital Diseases 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241001115458 Carphophis Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011509 Crystalluria Diseases 0.000 description 1
- 206010011894 Deafness permanent Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000011094 fiberboard Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000001144 hymen Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960004744 micronomicin Drugs 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940041024 other aminoglycosides in atc Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法,属于中药制备方法技术领域。目前治疗气滞血瘀型前庭大腺炎,一般采用西药治疗,其缺点是毒副作用大。该发明的技术方案为:取八仙草、八角莲、三颗针、大金钱草、马鞭草、毛冬青、水蓼、白头翁、白花蛇舌草、半枝莲、朱砂根、赤芍药、牡丹皮、败酱草、金盏银盘、夜关门、鬼针草、荷叶、臭草、野菊花、葎草、黑面叶和甘草,将以上23味中药放入1800毫升水中,浸泡30分钟,然后文火煎制30分钟,过滤去渣共煎药液390毫升,煎出的药液即为治疗气滞血瘀型前庭大腺炎的中药洗剂。它的优点是:制成的中药液毒副作用小,疗程短,治愈率高。君臣佐使,恰到好处。
Description
技术领域
本发明涉及中药洗剂制备方法技术领域,更具体的讲是一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法。
背景技术
目前治疗气滞血瘀型前庭大腺炎,一般采用:
1、哌拉西林:肌注后偶有局部疼痛,快速静脉推注可导致暂时性恶心、胸闷、咳嗽、发热、口腔异味、眼结膜充血,变态反应(皮疹、痒感、头晕、麻木、发热等),用药前必须注意青霉素有无过敏史,并做青霉素皮试。
2、阿莫西林:偶见皮疹,口服大量后可有恶心、上腹部不适、腹泻等;伪膜性结肠炎。
3、羧苄西林:可以出现各种类型的变态反应。大剂量给药后可能引起神经毒反应、肺水肿,用药期间可能出现短暂性转氨酶升高与粒细胞减少。
4、氨苄西林:大量口服常出现胃肠道不适。肌注局部有疼痛。无论口服或注射均可引起变态反应,以皮疹为多见。用药前必须先做皮试。
5、替卡西林钠克拉维酸钾:①过敏反应参见“青霉素”。②可见恶心、呕吐和腹泻等胃肠道反应以及肝脏功能改变AST或ALT增高,假膜性结肠炎罕见,个别报道可出现肝炎和胆汁淤积性黄疸。③肾功能不全或大剂量用本品有出现惊厥的报道。④局部静脉注射部位的血栓性静脉炎。
6、头孢噻肟:肌注局部可有疼痛;静注时可有血栓性静脉炎发生;皮疹、药物热等变态反应。
7、青霉素:本品易发生变态反应,特别是过敏性休克(最危险的过敏性休克,可发生在做皮肤试验的当时,极少数可发生在连续用药过程中,迟发性过敏性休克),如不及时抢救,可危急生命,故用药前、中、后都要提高防护,以免发生意外。注意:应用前,必须问清有无过敏性疾病,用青霉素后有无皮疹、发热等变态反应出现,务必先做青霉素皮试。
8、氨曲南:偶有味觉异常、皮疹、轻度胃肠道反应,肌注局部疼痛,静注可出现静脉炎。
9、卡那霉素:本品对听神经和肾脏均有毒性,前者表现为耳鸣、听力减退、甚至永久性耳聋(因以前庭损害为主,故比较严重),为此对老年人、孕妇(可影响胎儿)必须高度警惕为孕;后者表现为蛋白尿、管型尿等。
10、采用磺胺甲恶唑患者有时引起胃肠道反应、结晶尿、血尿、皮疹、药热及白细胞减少。
11、头孢哌酮:肌注局部可有疼痛;偶见皮疹、药物热等变态反应;个别病人可出现全血细胞减少、一过性转氨酶升高、凝血酶原时间延长或出血等。
12、头孢他啶:①肌注局部有疼痛;②偶可发生皮疹等变态反应;③肾功能不全或无尿患者宜减量或暂停。
13、头孢唑肟:①本品偶可致过敏,对可疑过敏病人特加防护;②用药期间可能出现胃肠道反应、肝功能改变、尿素氮增高、红细胞与血色素减少等。
14、阿米卡星:肾毒性与耳毒症状必然存在。偶有恶心、呕吐、头痛、发热、皮疹、震颤、感觉异常、关节疼痛、嗜酸粒细胞增多、贫血及低血压等。
15、小诺米星:①长期大量应用,可能引起听神经和肾脏毒害;②少数病人可出现皮疹等变态反应,对其他氨基糖甙类抗生素有过敏史者忌用;③肾功能减退及老年人慎用;④肝功能异常及孕妇慎用。
发明内容
为克服上述缺点,本发明的目的是发明一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法。大阴唇:为两股内侧的皮肤皱襞,左右各一。前接阴阜,两相会合形成阴唇前联合;后达会阴,两侧合成阴唇后联合。大阴唇分为内外两侧面:外侧面有阴毛、汗腺及皮脂腺;内侧面湿润似粘膜。大阴唇皮下富有脂肪组织、弹性纤维板及静脉丛,若受伤,易出血,形成血肿。小阴唇:位于大阴唇内侧,为类似鸡冠状的皮肤皱襞,酷似粘膜,左右各一,围绕阴道前庭。在大阴唇中、下1/3交界处,大小阴唇连成一片,左右两片又在正中线会合而成为一条横皱襞,称为阴唇系带。小阴唇内有较多皮脂腺与少数汗腺,神经末梢丰富,甚为敏感。前庭大腺:左右各一,位于大阴唇深部,约似黄豆大,腺管长且细,开口于小阴唇和处女膜之间的沟内,相当于阴道外口中、下1/3处。能分泌黄白色液体,以滑润阴道口。定义:前庭大腺炎是指前庭大腺侵入病原体如链球菌、葡萄球菌、大肠杆菌及霉菌、滴虫等通过粘膜蔓延、经血行散布、经淋巴扩散,直接蔓延等多种途径,引起的炎症。祖国医学记载:妇人阴户肿痛,甚或化脓溃疡,黄水淋沥;或阴户一侧凝结成块坚硬,或如蚕茧状者,总称“阴疮”,包括“阴肿”、“蚌疽”、“阴茧”、“阴蚀”等。阴疮,首见于《金匮要略》:“少阴脉滑而数者,阴中即生疮”,“阴中蚀疮烂者,狼牙汤洗之”。
病因病机:平时情志不畅,易恼怒,古人云:“气行则血行”,“气滞则血凝”,气滞血瘀,毒邪入侵会阴部,而发本病。
临床表现:胁痛,会阴部疼痛,易恼怒,善太息,会阴部有肿块。急性期腺体常肿胀变大,产生大量脓性分泌物。腺管口红肿外翻,挤压腺体可有脓性分泌物流出。重者同侧小阴唇亦红肿,终至整个腺体成为肿胀,局部压痛,行路困难,并出现体温及白细胞增高等周身症状。口干、大便秘结、小便涩滞,舌质暗红,苔黄,脉涩。
它的技术方案为:取八仙草6重量份、八角莲5重量份、三颗针6重量份、大金钱草6重量份、马鞭草6重量份、毛冬青6重量份、水蓼2重量份、白头翁6重量份、白花蛇舌草5重量份、半枝莲6重量份、朱砂根2重量份、赤芍药6重量份、牡丹皮6重量份、败酱草6重量份、金盏银盘6重量份、夜关门6重量份、鬼针草6重量份、荷叶8重量份、臭草3重量份、野菊花6重量份、葎草5重量份、黑面叶6重量份和甘草9重量份,将以上23味中药放入1800毫升水中,浸泡30分钟,然后文火煎制30分钟,过滤去渣共煎药液390毫升,煎出的药液即为治疗气滞血瘀型前庭大腺炎的中药洗剂。
该发明的优点是:本方23味中药,在药店均能买到,制作简单,制成的中药液毒副作用小,疗程短,治愈率高。君臣佐使,恰到好处。应用中药的同时,避免了西药抗菌素引起的不良反应、过敏反应和毒性反应。八仙草、八角莲、三颗针、大金钱草、马鞭草、毛冬青、水蓼、白头翁、白花蛇舌草、半枝莲、朱砂根、赤芍药、牡丹皮、败酱草、金盏银盘,以上15味药具有养阴清热,清热解毒,祛瘀消肿,益肾防劳,清热利湿,活血散瘀,解毒消肿,消毒散结,止咳化痰,泻下通便,祛风除痹,利水消肿,解毒疗疮,消积化痞,疏风解表,凉血止血,排脓生肌,清肝明目,健脾和胃,杀虫止痒之功效。在治疗气滞血瘀型前庭大腺炎的过程中,起主要治疗作用,故为君药。夜关门、鬼针草、荷叶、臭草、野菊花、葎草,以上6味药具有清热凉血,活血消瘀,祛瘀止痛,行血通络,凉血解毒之功效。在治疗气滞血瘀型前庭大腺炎的过程中,能辅助主药发挥治疗作用,故为臣药。黑面叶:苦,寒。入大肠、肝二经。清热解毒,化瘀止血。能率诸药直达病灶,故为佐药。甘草:甘,平。入十二经。补脾润肺,益气复脉,缓急止痛,清热解毒,调和药性。既能纠诸药之偏性,又能缓解诸药之毒性,故为使药。八仙草、八角莲、三颗针、大金钱草、马鞭草、毛冬青、水蓼、白头翁、白花蛇舌草、半枝莲、朱砂根、赤芍药、牡丹皮、败酱草、金盏银盘、夜关门、鬼针草、荷叶、臭草、野菊花、葎草、黑面叶、甘草,这23味药配伍应用,共同起到清热解毒、利水消肿,消肿止痛,凉血止血,行瘀排脓,清热凉血,活血消瘀,行血通络之功效。君臣佐使,配伍得当,是治疗气滞血瘀型前庭大腺炎的最佳配方。八仙草:辛、苦,寒。入心、肺二经。清热利湿,活血散瘀,解毒消肿。八角莲:苦、辛,平。入心、肺、肾三经。清热解毒,祛瘀消肿,止咳化痰,益肾防劳。三颗针:苦、寒,无毒。入肝、胃、大肠三经。清热利湿,清肝明目,散瘀消肿。大金钱草:甘、咸,微寒。入肝、胆、肾、膀胱四经。清热利湿,和胃降逆,解毒消肿,祛瘀消肿。马鞭草:苦、辛,寒。入肝、脾二经。清热解毒,活血散瘀,利水消肿,截疟。毛冬青:微苦、甘,平。入肺、肝、大肠三经。清热解毒,活血通络,利水渗湿。水蓼:辛,温。入心经。祛湿止泻,散瘀止痛,解毒消肿,杀虫疗疮。白头翁:苦,寒。入大肠、肝、胃三经。清热解毒,凉血散瘀,截疟,清肝明目。白花蛇舌草:苦、甘,寒。入心、肝、脾三经。清热解毒,清热利湿,清热散瘀,小儿疳积。半枝莲:辛、微苦,平。入心、肺、肝、肾四经。清热解毒,止血,散瘀止痛,行气利水。朱砂根:辛、苦,寒。入肺、脾、胃三经。清热解毒,散瘀止痛。赤芍药:酸、苦,凉。入肝、脾二经。祛瘀止痛,清热凉血,利水通淋。牡丹皮:辛、苦,凉。入心、肝、肾三经。清热凉血,消瘀散结。败酱草:辛、苦,微寒。入胃、大肠、肝三经。清热解毒,消痈化脓,祛瘀止痛,凉血止血,杀虫止痒。金盏银盘:苦、甘、淡,平。入肺、大肠、脾、胃四经。疏风清热,清热解毒,活血化瘀,消食化积。夜关门:苦、辛,凉。入肺、肝、肾三经。补益肝肾,止咳平喘,消肿散瘀,益肝明目。鬼针草:苦,平,无毒。入肺、胃、大肠、胆四经。散瘀消肿,截疟退热,止泻除痢,清热退黄,清热消肿,解虫蛇毒。荷叶:苦、涩、辛、微咸,凉。入心、肝、肾、脾、胃五经。清暑利湿,升发阳气,祛瘀止血,固精、涩遗。臭草:苦、辛,寒。入肺、肾、肝、心四经。祛风退热,清热解毒,利水消肿,活血化瘀,凉血止血,行气渗湿。野菊花:苦、甘、辛,凉。入肺、二肝经。疏风清热,解毒消肿,疏肝破血。葎草:甘、苦,寒,无毒。入肺、肾、大肠三经。清热解毒,利尿消肿,消瘀散结。黑面叶:苦,寒。入大肠、肝二经。清热解毒,化瘀止血。甘草:甘,平。入十二经。补脾润肺,益气复脉,缓急止痛,清热解毒,调和药性。
具体实施方式:取八仙草6g、八角莲5g、三颗针6g、大金钱草6g、马鞭草6g、毛冬青6g、水蓼2g、白头翁6g、白花蛇舌草5g、半枝莲6g、朱砂根2g、赤芍药6g、牡丹皮6g、败酱草6g、金盏银盘6g、夜关门6g、鬼针草6g、荷叶8g、臭草3g、野菊花6g、葎草5g、黑面叶6g和甘草9g,将以上23味药一起放入1800毫升水中,浸泡30分钟,然后文火煎制30分钟,过滤去渣,煎出的药液即为治疗气滞血瘀型前庭大腺炎的中药洗剂。共煎药液390毫升,当气滞血瘀型前庭大腺炎的病人需要治疗时,使药液温度为35℃,每次130毫升,擦洗患处,每日三次, 二日为一疗程,若症状仍存,再洗第二疗程,以至痊愈。
气滞血瘀型前庭大腺炎患者共369例.
表一、369例气滞血瘀型前庭大腺炎患者的年龄范围
年龄(岁) | 20~30 | 31~35 | 36~40 | 41~45 |
例数 | 15 | 219 | 127 | 8 |
百分比 | 4.1% | 59.4% | 34.4% | 2.1% |
表二、369例气滞血瘀型前庭大腺炎患者疗效表
疗效 | 治愈 | 好转 | 无效 |
例数 | 366 | 3 | 无 |
百分比 | 99.2% | 0.8% | 无 |
表三、369例气滞血瘀型前庭大腺炎患者疗程表
治疗天数 | 3~5 | 6~9 | 10~14 | 15~21 |
例数 | 13 | 199 | 151 | 6 |
百分比 | 3.5% | 54% | 40.9% | 1.6% |
表四、369例气滞血瘀型前庭大腺炎患者治疗前后情况表
Claims (1)
1.一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法,其特征是:取八仙草6克、八角莲5克、三颗针6克、大金钱草6克、马鞭草6克、毛冬青6克、水蓼2克、白头翁6克、白花蛇舌草5克、半枝莲6克、朱砂根2克、赤芍药6克、牡丹皮6克、败酱草6克、金盏银盘6克、夜关门6克、鬼针草6克、荷叶8克、臭草3克、野菊花6克、葎草5克、黑面叶6克和甘草9克,将以上23味中药放入1800毫升水中,浸泡30分钟,然后文火煎制30分钟,过滤去渣共煎药液390毫升,煎出的药液即为治疗气滞血瘀型前庭大腺炎的中药洗剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013104588501A CN103463314A (zh) | 2013-10-07 | 2013-10-07 | 一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013104588501A CN103463314A (zh) | 2013-10-07 | 2013-10-07 | 一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103463314A true CN103463314A (zh) | 2013-12-25 |
Family
ID=49788506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013104588501A Pending CN103463314A (zh) | 2013-10-07 | 2013-10-07 | 一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103463314A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258037A (en) * | 1976-12-02 | 1981-03-24 | Sertog Societe D'etudes De Recherches De Travoux D'organisation Et De Gestion | Therapeutic compounds for the treatment of uro-genital disorders |
CN103230523A (zh) * | 2013-04-30 | 2013-08-07 | 田桂菊 | 一种治疗面赤型脓性指头炎的中药洗剂制备方法 |
CN103251807A (zh) * | 2013-05-25 | 2013-08-21 | 杜守勤 | 一种治疗肝郁化火型贲门炎的中药制备方法 |
CN103285180A (zh) * | 2013-05-25 | 2013-09-11 | 王德章 | 一种治疗过食烤羊肉串型贲门炎的中药制备方法 |
-
2013
- 2013-10-07 CN CN2013104588501A patent/CN103463314A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258037A (en) * | 1976-12-02 | 1981-03-24 | Sertog Societe D'etudes De Recherches De Travoux D'organisation Et De Gestion | Therapeutic compounds for the treatment of uro-genital disorders |
CN103230523A (zh) * | 2013-04-30 | 2013-08-07 | 田桂菊 | 一种治疗面赤型脓性指头炎的中药洗剂制备方法 |
CN103251807A (zh) * | 2013-05-25 | 2013-08-21 | 杜守勤 | 一种治疗肝郁化火型贲门炎的中药制备方法 |
CN103285180A (zh) * | 2013-05-25 | 2013-09-11 | 王德章 | 一种治疗过食烤羊肉串型贲门炎的中药制备方法 |
Non-Patent Citations (3)
Title |
---|
冉先德: "《中华药海》", 31 August 1993, 哈尔滨出版社 * |
山东医学院中医系外科教研室: "《中医外科学》", 30 June 1973, 山东人民出版社 * |
李元文等: "《中医性学》", 31 January 2013, 北京科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103463508A (zh) | 一种治疗过食烤鱼型前庭大腺炎的中药洗剂制备方法 | |
CN103463447A (zh) | 一种治疗目赤型前庭大腺炎的中药洗剂制备方法 | |
CN103446359A (zh) | 一种治疗过食肥肉型前庭大腺炎的中药洗剂制备方法 | |
CN103463504A (zh) | 一种治疗咳嗽型前庭大腺炎的中药洗剂制备方法 | |
CN103446487A (zh) | 一种治疗过食干姜型前庭大腺炎的中药洗剂制备方法 | |
CN103479885A (zh) | 一种治疗溲赤型前庭大腺炎的中药洗剂制备方法 | |
CN103463319A (zh) | 一种治疗嗜食鲜姜型前庭大腺炎的中药洗剂制备方法 | |
CN103446446A (zh) | 一种治疗热毒型前庭大腺炎的中药洗剂制备方法 | |
CN103463328A (zh) | 一种治疗嗜食猪肝型前庭大腺炎的中药洗剂制备方法 | |
CN103463507A (zh) | 一种治疗嗜食大蒜型前庭大腺炎的中药洗剂制备方法 | |
CN103446448A (zh) | 一种治疗搔痒型前庭大腺炎的中药洗剂制备方法 | |
CN103230543A (zh) | 一种治疗嗜食芥茉型脓性指头炎的中药洗剂制备方法 | |
CN103463314A (zh) | 一种治疗气滞血瘀型前庭大腺炎的中药洗剂制备方法 | |
CN103463445A (zh) | 一种治疗肿胀型前庭大腺炎的中药洗剂制备方法 | |
CN103446447A (zh) | 一种治疗嗜食酸菜型前庭大腺炎的中药洗剂制备方法 | |
CN103446353A (zh) | 一种治疗过食川椒型前庭大腺炎的中药洗剂制备方法 | |
CN103463353A (zh) | 一种治疗出血型前庭大腺炎的中药洗剂制备方法 | |
CN103479925A (zh) | 一种治疗痰火内扰型前庭大腺炎的中药洗剂制备方法 | |
CN103463327A (zh) | 一种治疗嗜食芥茉型前庭大腺炎的中药洗剂制备方法 | |
CN103494971A (zh) | 一种治疗嗜食胡椒型前庭大腺炎的中药洗剂制备方法 | |
CN103495033A (zh) | 一种治疗过食高热食品型前庭大腺炎的中药洗剂制备方法 | |
CN103463320A (zh) | 一种治疗嗜食熏鸡型前庭大腺炎的中药洗剂制备方法 | |
CN103463448A (zh) | 一种治疗口渴型前庭大腺炎的中药洗剂制备方法 | |
CN103479924A (zh) | 一种治疗心火炽盛型前庭大腺炎的中药洗剂制备方法 | |
CN103479834A (zh) | 一种治疗肿块型前庭大腺炎的中药洗剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131225 |